12 results about "Hepatic tissue" patented technology

The invention provides a lesion characteristic hepatic region spatial distribution analysis method and system of a hepatic tissue pathological image. A layered framework is constructed based on hepatic tissue physiological structure logic. According to the system, the internal region of an analysis object of a pathological image, the analysis object and a hepatic lobule object are accurately segmented through an object segmentation model, and analysis object lesion features, analysis object units and relative spatial position information of the analysis object are respectively extracted. Lesion features and relative spatial position information are further fused, a hepatic region coordinate algorithm is constructed, hepatic region coordinate calculation of all sites in the whole pathological image is achieved, and subjectivity and quantization errors of a traditional method are overcome. And finally, the system counts and analyzes the lesion features of the object and the coordinate information of the hepatic region, establishes and realizes accurate and objective analysis of the lesion features in the hepatic tissue pathological image along with the spatial distribution of the hepatic region, and solves the technical bottleneck of total-graph quantitative analysis of the spatial distribution of the hepatic region in the hepatic tissue pathological image.

The invention discloses a preparation method of luteolin-loaded targeted polypeptide nanoparticles and application of the luteolin-loaded targeted polypeptide nanoparticles in hepatic fibrosis treatment, and belongs to the technical field of nano-drug delivery and liver disease treatment. The luteolin-loaded targeted polypeptide nanoparticles are used for treating or relieving liver fibrosis related diseases. According to the nanoparticle disclosed by the invention, a stable structure is formed through self-assembly of the amphiphilic polymer, the luteolin is physically entrapped, targeted delivery of liver immune cells is realized, and the nanoparticle shows good biocompatibility and safety in an in-vivo macrophage polarization and liver fibrosis model; the inflammatory response and collagenous fiber deposition can be remarkably inhibited, and the hepatic tissue fibrosis degree is improved. Compared with the existing anti-hepatic fibrosis medicine which has the problems of poor targeting property, low bioavailability, obvious side effect after long-term medication and the like, the luteolin-loaded targeting polypeptide nanoparticle has the remarkable advantages of high delivery efficiency, strong targeting property, good safety, stable treatment effect and the like.

Disclosed herein are hepato-biliary-pancreatic organoid (“HBPO” or “HBP organoid”) compositions, and methods of making and using hepato-biliary-pancreatic organoid compositions. The disclosed compositions may have two or more functions selected from hepatic tissue function, biliary tissue function, exocrine pancreatic function, and endocrine pancreatic tissue function. Methods of treating individuals using the hepato-biliary-pancreatic organoid compositions is also disclosed.

Double-stranded oligonucleotides are provided herein that provide increased inhibition or reduction of expression of target genes in extra-hepatic tissue compared to hepatocytes. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and / or conditions associated with an RNAi trigger induced decrease in target gene expression.

The invention discloses application of curcumenone in preparation of a medicine for preventing and treating ischemia-reperfusion injury. The invention proposes and verifies that the caramel curcumenone can be used for preventing and treating the hepatic ischemia reperfusion injury for the first time, and the compound can effectively protect hepatic tissues and avoid liver function damage by inhibiting the oxidative stress level of the hepatic tissues after ischemia reperfusion, avoiding cell ferroptosis and improving bone marrow-derived macrophages, so that the caramel curcumenone can be used for preventing and treating the hepatic ischemia reperfusion injury. The invention provides a novel medicine with great application potential for preventing and treating ischemia reperfusion injury.

The invention discloses an establishment method and application of a type-1 autoimmune hepatitis mouse model, and relates to the technical field of biology, and the technical key points are as follows: an adenovirus is combined with an overexpression Sepsecs plasmid to realize continuous expression of autoantigen in the liver, a chronic liver inflammation model conforming to type-1 AIH characteristics is successfully induced in a mouse body for the first time, and the mouse model has a good application prospect. The model shows clinical pathological characteristics of continuous infiltration of inflammatory cells, abnormal liver function, autoantibody generation, hepatic tissue fibrosis and the like, and has good stability and repeatability. At present, no type 1 AIH mouse model constructed by using the Sepsecs antigen is publically reported at home and abroad, and the technical blank in the field of type 1 AIH chronic animal models is filled. The model can be used for AIH pathogenesis research, autoantigen screening, novel diagnostic marker discovery, immune intervention means evaluation and clinical verification before new medicine, has wide scientific research and industrial application prospects, and provides an ideal experimental animal model platform.

This invention discloses the application of primrosein in the preparation of drugs for the treatment of liver fibrosis. The chemical name of primrosein is 2-methoxy-6-pentyl-1,4-benzoquinone, and its molecular formula is C2. 12 O3H 16 Cellular experiments showed that primrosein reduced the proliferative activity of hepatic stellate cells but did not increase the release of lactate dehydrogenase from hepatic stellate cells, and had no significant inhibitory effect on hepatocyte proliferation. Animal experiments showed that primrosein reduced serum levels of markers in carbon tetrachloride-induced liver fibrosis model mice, decreased collagen fiber content in their liver tissue, and inhibited the expression of hepatic stellate cell activation markers, demonstrating excellent anti-liver fibrosis effects. This indicates that primrosein can be used to prepare effective drugs for the treatment of liver fibrosis.

The invention belongs to the technical field of medicines, and particularly relates to application of sophora alcohol O in preparation of anti-hepatic fibrosis medicines. The invention provides the application of the sophora alcohol O in preparing the anti-hepatic fibrosis medicine for the first time, for example, the sophora alcohol O can be applied to preparing the medicine for preventing or treating hepatic cell fibrosis and mouse hepatic tissue fibrosis. The compound also can be used for preparing medicines for inhibiting proliferation or activation of hepatic stellate cells, inhibiting hepatic fibrosis in a living body, inhibiting level rise of fibronectin (FN), inhibiting level rise of alpha-smooth muscle actin (alpha-SMA), inhibiting level rise of type I collagen (collagen I, collagen II, collagen III, collagen III, collagen IV and the like), and inhibiting liver fibrosis in a living body, level rise of fibronectin (FN, FN), level rise of alpha-smooth muscle actin (alpha-SMA) and level rise of alpha-SMA. The invention relates to a medicine for inhibiting the level rise of alanine aminotransferase (ALT) in mouse serum, inhibiting the level rise of aspartate aminotransferase (AST) in mouse serum and inhibiting the level rise of hydroxyproline (HYP) in mouse liver tissue, and the medicine has good patent medicine potential and wide development, transformation and clinical application values and prospects.

The invention discloses application of tussilagone in preparation of a medicine for resisting radiation injury, and belongs to the technical field of biology. The technical problem to be solved by the invention is how to resist radiation damage. The application provided by the invention specifically refers to application of tussilagone in preparation of a product for treating or / and relieving body injury caused by radiation. Experiments prove that tussilagone can effectively relieve hyperemia and bleeding and inflammatory cell infiltration of pulmonary alveoli of mice after radiation; the hepatic cord structure damage and hepatic sinus hyperemia in the hepatic tissue are relieved; disorder and vacuolation of a bone marrow structure can be relieved, and recovery of hematopoietic cells in bone marrow is promoted; edema and shedding of intestinal villi can be relieved, and the integrity of the intestinal structure can be partially repaired; and hair follicle structure damage and fiber bundle hyperplasia in skin tissues are improved.

Provided herein are in silico methods of modeling hepatic inflammation, fibrosis / cirrhosis, and cancer. The models are computer-implemented agent-based models and are useful in determining patient prognoses in hepatic conditions, including viral infections, damage, inflammation, and cancer. The modeling system also is useful in modeling the effects of active agents on normal hepatic tissue or hepatic tissue perturbed by inflammation, infection, damage, fibrosis / cirrhosis, and cancer.